Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Memorial Hospital For Cancer And Allied Diseases maintains a patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The organization currently faces 7 pending office actions, which are distributed across 7 distinct examiners. This distribution of 7 pending actions across 7 examiners suggests a broad allocation of legal matters across the patent office staff.
The prosecution activity spans 6 distinct art units, reflecting a diverse range of technical examinations within the biotechnology sector. This variety in art units indicates that the hospital's intellectual property strategy touches upon multiple specialized technical classifications simultaneously.
CONNORS, ALEXANDRA F is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. Because the busiest examiner's workload of 1 pending action is equal to the workload of every other examiner involved, the portfolio's pending office actions are perfectly distributed across the distinct examiners currently engaged with the hospital's filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 1 (14%) |
| §102 only | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CONNORS, ALEXANDRA F | 1 | 23.9% | +45.4% |
| PYLA, EVELYN Y | 1 | 55.7% | +47.1% |
| QIAN, CELINE X | 1 | 47.6% | +16.9% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
| AMICK, THOMAS RUSSE | 1 | 73.1% | +30.4% |
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18889101 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | CONNORS, ALEXANDRA F | — |
| 18542134 | METHODS OF GENERATING SACRAL NEURAL CREST LINEAGES AND USES THEREOF | PYLA, EVELYN Y | — |
| 18306890 | CELLS WITH CD70 KNOCKOUT AND USES FOR IMMUNOTHERAPY | QIAN, CELINE X | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18155115 | METHODS OF TREATING LEPTOMENINGEAL METASTASIS | WHITE, DAWANNA SHAR-DAY | 28d |
| 18889101 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | CONNORS, ALEXANDRA F | — |
| 18542134 | METHODS OF GENERATING SACRAL NEURAL CREST LINEAGES AND USES THEREOF | PYLA, EVELYN Y | — |
| 18306890 | CELLS WITH CD70 KNOCKOUT AND USES FOR IMMUNOTHERAPY | QIAN, CELINE X | — |
| 17831638 | CELLS EXPRESSING C-KIT MUTATIONS AND USES THEREOF | AMICK, THOMAS RUSSE | — |
| 17590585 | CELLS FOR IMPROVED IMMUNOTHERAPY AND USES THEREOF | GODDARD, LAURA B | — |
| 17578989 | FUSION POLYPEPTIDE FOR IMMUNOTHERAPY | MIANO, JOSEPH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| 1637 | 1 |
| 1627 | 1 |
| 1638 | 1 |
| 1600 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18889101 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | CONNORS, ALEXANDRA F | — | §103§112 | Non-Final OA | — | Pending | Sep 18, 2024 |
| 18542134 | METHODS OF GENERATING SACRAL NEURAL CREST LINEAGES AND USES THEREOF | PYLA, EVELYN Y | 1633 | §102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18306890 | CELLS WITH CD70 KNOCKOUT AND USES FOR IMMUNOTHERAPY | QIAN, CELINE X | 1637 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 25, 2023 |
| 18155115 | METHODS OF TREATING LEPTOMENINGEAL METASTASIS | WHITE, DAWANNA SHAR-DAY | 1627 | §103Other | Non-Final OA | 28d | Pending | Jan 17, 2023 |
| 17831638 | CELLS EXPRESSING C-KIT MUTATIONS AND USES THEREOF | AMICK, THOMAS RUSSE | 1638 | §112 | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17590585 | CELLS FOR IMPROVED IMMUNOTHERAPY AND USES THEREOF | GODDARD, LAURA B | 1600 | §102 | Final Rejection | — | Pending | Feb 01, 2022 |
| 17578989 | FUSION POLYPEPTIDE FOR IMMUNOTHERAPY | MIANO, JOSEPH PAUL | 1631 | §102§103§112DP | Final Rejection | — | Pending | Jan 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial